- Home
- DBRG vs OLMA Comparison
DBRG vs OLMA Comparison
Compare DBRG & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBRG | OLMA |
|---|---|---|
| Founded | 1991 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DBRG | OLMA |
|---|---|---|
| Price | $15.42 | $25.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $16.00 | ★ $41.14 |
| AVG Volume (30 Days) | ★ 4.6M | 1.3M |
| Earning Date | 02-20-2026 | 03-17-2026 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $100,346,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $189.77 | N/A |
| P/E Ratio | $252.58 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.41 | $2.86 |
| 52 Week High | $15.55 | $36.26 |
Technical Indicators
Market Signals| Indicator | DBRG | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 67.13 | 49.49 |
| Support Level | $15.32 | $24.91 |
| Resistance Level | $15.45 | $27.13 |
| Average True Range (ATR) | 0.07 | 1.67 |
| MACD | -0.10 | -0.11 |
| Stochastic Oscillator | 51.43 | 60.87 |
Price Performance
Historical ComparisonAbout DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.